Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive tags : Biotech-bay save search
Tenon(R) Medical Announces Positive Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran(R) SI Joint Fusion System
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
TNON | $0.7101 460
|
|
| O: 2.54%
H: 1.98%
C: -5.45%
first positive system medical results study
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsCompany maintains solid cash position of $158.9 million
Published: 2024-03-07 (Crawled : 15:30) - biospace.com/
RAPT | $7.995 -0.06% 18K
|
Health Technology
|
| O: 0.66%
H: 4.57%
C: 0.87%
year million therapeutics financial
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
Published: 2024-02-28 (Crawled : 19:00) - biospace.com/
VANI | $1.8 13K
|
Manufacturing
|
| O: 499.01%
H: 28.93%
C: -38.18%
npm-115 ozempic obesity positive preclinical medical
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Published: 2023-06-23 (Crawled : 14:00) - biospace.com/
GILD | $66.85 -0.27% 1M
|
Health Technology
|
| O: 0.28%
H: 0.04%
C: -1.1%
trodelvy chmp breast positive cancer
GRAIL Presents Positive Analytical Validation Data on its Methylation-Based Post-Diagnostic Cancer Research Solution at American Association for Cancer Research (AACR) Annual Meeting 2023
Published: 2023-04-19 (Crawled : 21:00) - biospace.com/
ILMN | $122.54 -1.54% 84K
|
Health Technology
|
| O: -1.0%
H: 2.76%
C: 2.48%
association solution positive cancer research meeting
Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine
Published: 2023-04-17 (Crawled : 23:00) - biospace.com/
ANIX | $3.26 6.19% 62K
|
Health Technology
|
| O: 1.84%
H: 6.09%
C: -25.82%
vaccine breast positive cancer study
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
Published: 2023-03-22 (Crawled : 14:00) - biospace.com/
VTGN | $4.83 22K
|
Health Technology
|
| O: 30.64%
H: 14.42%
C: -10.93%
ph94 positive study social anxiety disorder
Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management
Published: 2023-02-27 (Crawled : 16:00) - biospace.com/
SCLX | $0.9129 -6.53% 310K
|
|
| O: 1.92%
H: 4.12%
C: -0.59%
SRNE | $0.015 56K
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: -29.07%
management commercial
Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results
Published: 2022-12-08 (Crawled : 12:20) - biospace.com/
BTTX | $0.006 340K
|
|
| O: -1.41%
H: 8.56%
C: 3.59%
liver disease topline trial therapeutics positive
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
Published: 2022-11-04 (Crawled : 17:00) - biospace.com/
ADVM | News | $11.02 0.18% 15K
|
Health Technology
|
| O: 1.32%
H: 14.6%
C: -3.5%
advm-022 trial positive injection results study
Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)
Published: 2022-10-24 (Crawled : 13:00) - biospace.com/
MIRM | $24.14 -1.15% 24K
|
Health Technology
|
| O: 1.28%
H: 2.98%
C: 1.26%
topline livmarli positive study
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older
Published: 2022-10-14 (Crawled : 15:20) - biospace.com/
MIRM | $24.14 -1.15% 24K
|
Health Technology
|
| O: 0.99%
H: 4.96%
C: 4.2%
livmarli pharmaceuticals pruritus chmp positive
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Published: 2022-10-14 (Crawled : 15:20) - biospace.com/
ATRA | $0.701 -2.45% 58K
|
Health Technology
|
| O: 3.76%
H: 0.47%
C: -9.9%
treatment disease chmp approval
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
Published: 2022-10-11 (Crawled : 19:00) - biospace.com/
DICE | $47.55 0.06% 0.08% 0
|
|
| O: 79.23%
H: 4.1%
C: -9.46%
il-17 topline trial therapeutics psoriasis positive
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
Published: 2022-10-06 (Crawled : 15:00) - biospace.com/
PLSE | $6.77 -1.31% 39K
|
Health Technology
|
| O: -0.38%
H: 0.62%
C: -9.47%
positive cell carcinoma
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
Published: 2022-09-16 (Crawled : 11:00) - biospace.com/
GILD | $66.85 -0.27% 1M
|
Health Technology
|
| O: 0.12%
H: 1.31%
C: 0.8%
covid-19 veklury treatment chmp positive
Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy
Published: 2022-09-01 (Crawled : 14:20) - biospace.com/
NVRO | $13.22 3.36% 76K
|
Health Technology
|
| O: -1.54%
H: 1.28%
C: 0.85%
treatment positive diabetic
Imperative Care Announces Positive New Data Underscoring the Safety and Efficacy of the Zoom Stroke Solution to Treat Distal Occlusions in Ischemic Stroke Patients
Published: 2022-08-24 (Crawled : 12:20) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 0.0%
H: 5.0%
C: 0.83%
care stroke positive
RAPT Therapeutics Reports Second Quarter 2022 Financial ResultsCompany maintains strong cash position of $207.3 million
Published: 2022-08-11 (Crawled : 13:00) - biospace.com/
RAPT | $7.995 -0.06% 18K
|
Health Technology
|
| O: 0.89%
H: 7.21%
C: 2.14%
therapeutics
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis
Published: 2022-08-10 (Crawled : 22:00) - biospace.com/
RANI | $6.69 5.3K
|
|
| O: 3.82%
H: 0.79%
C: -2.76%
rt-102 topline therapeutics positive results study osteoporosis phase 1
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.78 52.14% 15M
|
SYRA | $1.5 51.23% 1M
|
n/a
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
RILY | $30.325 39.62% 6.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
TROO | $1.41 29.36% 280K
|
Manufacturing
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.